Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results....

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a sho...

The Investment Committee debate the latest Calls of the Day....

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow tr...

Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repu...

California Public Employees Retirement System reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 33.5% in the second quarter, according to its most recent 13F filing w...

Bank of Nova Scotia lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 103.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...

Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first p...